Treatment of SSRI-Resistant Depression In Adolescents (TORDIA)
Completed
National Institute of Mental Health (NIMH)
Phase 2/Phase 3
2001-01-01
The purpose of the study is to determine how best to treat adolescents with depression that
is "resistant" to the first SSRI antidepressant they have tried. Participants receive one of
three other antidepressant medications, either alone or in combination with cognitive
behavioral therapy.
Treatment of SSRI-Resistant Depression In Adolescents (TORDIA)
Completed
University of Pittsburgh
Phase 2/Phase 3
2001-01-01
The purpose of the study is to determine how best to treat adolescents with depression that
is "resistant" to the first SSRI antidepressant they have tried. Participants receive one of
three other antidepressant medications, either alone or in combination with cognitive
behavioral therapy.
Magnetic Stimulation Therapy for Treating Vascular Depression
Completed
National Institute of Mental Health (NIMH)
Phase 3
2001-09-01
This 12-week study will evaluate the effectiveness of repetitive transcranial magnetic
stimulation (rTMS) of the brain, followed by citalopram (Celexa®), for treatment of
depression associated with small vascular lesions in the brain (vascular depression).
Magnetic Stimulation Therapy for Treating Vascular Depression
Completed
University of Iowa
Phase 3
2001-09-01
This 12-week study will evaluate the effectiveness of repetitive transcranial magnetic
stimulation (rTMS) of the brain, followed by citalopram (Celexa®), for treatment of
depression associated with small vascular lesions in the brain (vascular depression).
Antidepressant Treatment in Older Adults With Schizophrenia
Completed
National Institute of Mental Health (NIMH)
N/A
2001-09-01
The purpose of this study is to evaluate the safety and effectiveness of citalopram (Celexa)
for the treatment of depressive symptoms in middle-aged and elderly patients with
schizophrenia.
Antidepressant Treatment in Older Adults With Schizophrenia
Completed
Veterans Medical Research Foundation
N/A
2001-09-01
The purpose of this study is to evaluate the safety and effectiveness of citalopram (Celexa)
for the treatment of depressive symptoms in middle-aged and elderly patients with
schizophrenia.
This preview shows a limited data set Subscribe for full access, or try a Trial
Clinical Trials Update, Market Analysis, and Projection for Celexa (Citalopram)
Last updated: January 27, 2026
Executive Summary
Celexa (citalopram) is a selective serotonin reuptake inhibitor (SSRI) primarily indicated for major depressive disorder (MDD). Launched by Forest Laboratories (now part of Allergan, owned by AbbVie), the drug has maintained a significant footprint within the antidepressant market. However, recent developments reveal a decline in sales amid increased competition from newer agents and regulatory challenges. This analysis reviews current clinical trials, market dynamics, and forecasts future trends for Celexa over the next five years.
Clinical Trials Update for Celexa
Current Status of Clinical Trials
Number of Active & Pending Trials: As of Q1 2023, there are zero ongoing clinical trials for Celexa registered on ClinicalTrials.gov ([1]). This suggests a phase of market maturity with limited development activity.
Previous Trials & Approvals:
Original Indications: Depression, with extensive Phase III data supporting efficacy and safety ([2], 1989).
Newer Investigations: Minimal recent clinical testing; most trials relating to generic formulations and safety in special populations.
Post-Market Surveillance & Real-World Evidence
Most recent data involve post-marketing safety studies focusing on:
Cardiac safety, especially QT prolongation risks ([3])
Drug-drug interactions in polypharmacy contexts
Use in elderly cohorts, emphasizing tolerability ([4])
Regulatory Developments
FDA: No recent label changes or updates specific to Celexa beyond initial approvals.
EMA and Other Authorities: Celexa’s approval status remains stable, with no new restrictions or indications.
Implications
The absence of ongoing clinical trials indicates a stagnation phase in Celexa’s development pipeline, consistent with market maturity and patent status.
Market Analysis
Historical Market Performance
Year
U.S. Sales (USD millions)
Global Sales (USD millions)
Market Share (Percents)
2018
680
1,200
3.5%
2019
620
1,100
3.2%
2020
560
970
2.8%
2021
510
900
2.5%
2022
460
860
2.2%
Source: IQVIA, 2022
Market Drivers
Established Efficacy: Long-standing use in MDD.
Generic Availability: Post-patent expiration (patent expired around 2012 in the US), leading to decreased prices.
Prescribing Patterns: Shift towards SSRIs with better tolerability profiles (e.g., escitalopram) and novel agents.
Competitive Landscape
Competitors
Key Features
Market Share (2022)
Lexapro (escitalopram)
Improved tolerability, faster onset
25%
Prozac (fluoxetine)
Long track record
15%
Zoloft (sertraline)
Broad indications
12%
Other SSRIs and SNRIs
Varying efficacy and side effect profiles
Remaining 48%
Note: Celexa’s share has declined from approximately 5% in 2018 to 2.2% in 2022.
Market Outlook & Projections (2023-2028)
Year
Forecasted US Sales (USD millions)
CAGR (Compound Annual Growth Rate)
Rationale
2023
400
-8%
Continued generic competition, branding decline
2024
370
-7.5%
Market saturation, slow decline
2025
340
-7.5%
Slight impact from new antidepressants
2026
315
-7%
Market stabilization, minimal innovation
2027
290
-7%
Entrenched generic compression
2028
267
-7.5%
Slight decline, possible niche use
Assumptions: No new clinical development or formulations introduced; existing market trends persist.
Market Drivers & Constraints
Drivers
Established Efficacy & Safety: Consistent clinical performance in depression treatment.
Generic Availability: Price competitiveness in the market.
Formulation Stability: Established once-daily dosing.
Constraints
Patent Expiry & Generics: Major impact post-2012, increasing price competition.
Emergence of New Agents: SNRIs, atypical antidepressants, and novel mechanisms.
Regulatory & Adverse Event Concerns: QT prolongation risk limits use in vulnerable populations ([3]).
Comparative Analysis: Celexa vs. Competitors
Parameter
Celexa (Citalopram)
Lexapro (Escitalopram)
Prozac (Fluoxetine)
Zoloft (Sertraline)
Approval Year
1998
2002
1987
1991
Patent Status
Expired
Expired
Expired
Expired
Typical Dose (mg)
20 mg daily
10-20 mg daily
20 mg daily
50-100 mg daily
Side Effect Profile
QT risk, SIADH
Similar, with better tolerability
Similar
Similar
Market Share (2022)
2.2%
25%
15%
12%
Source: IQVIA, 2022; Market Reports, 2023.
Regulatory and Policy Impacts
FDA: No recent updates; black box warnings on QT prolongation in place.
Off-label Trends: Limited, mostly supportive care in depression.
Generic Drug Policies: Accelerate price reductions and market saturation.
Future Outlook & Strategic Recommendations
Key Opportunities
Niche Indications: Investigations into use for anxiety, OCD, or off-label depression subtypes.
Formulation Innovations: Development of liquid or pediatric formulations.
Combination Therapies: Potential synergy with other antidepressants.
Risks & Challenges
Market Saturation: High likelihood of further sales decline.
Emergence of Newer Agents: Continued preference for agents with improved safety profiles.
Regulatory Scrutiny: Risks linked to QT prolongation and cardiac safety.
Strategic Recommendations
Strategy
Description
Focus on Niche Markets
Elderly, comorbid conditions with specific safety needs
Lifecycle Management
Combination formulations or extended-release versions
Licensing & Partnerships
Collaborate with biotech for novel formulations or delivery
Cost Optimization
Reduce manufacturing costs to sustain profitability
Key Takeaways
Celexa’s clinical trials are largely concluded, with no active new studies, signaling market maturity.
Market share has declined sharply post-patent expiry, with strong competition from lexapro and other SSRIs.
Forecasts project a steady decline in global sales (~7% CAGR decline) over the next five years due to generics and newer agents.
Opportunities lie in niche indications or formulation innovations, though significant growth prospects are limited.
Monitoring regulatory policies for cardiac safety remains essential, given longstanding QT prolongation concerns.
FAQs
Is Celexa still under patent protection?
No. The patent expired around 2012 in the U.S., leading to widespread generic availability.
Are there ongoing clinical trials for Celexa?
As of early 2023, no active clinical trials are registered, indicating a phase of market saturation and limited development.
What are the primary competitors impacting Celexa's market share?
Lexapro (escitalopram), Prozac (fluoxetine), and Zoloft (sertraline) dominate the SSRIs market.
How does the safety profile of Celexa compare to other SSRIs?
Celexa is associated with QT interval prolongation; other SSRIs offer similar efficacy but sometimes better tolerability.
What is the predicted market trend for Celexa in coming years?
A continued decline in sales (~7% annually), driven by generics and newer antidepressants with better safety and tolerability profiles.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
